ARCT-154 (V-0216)
COVID-19 (Primary Series & Boosters)
Key Facts
Indication
COVID-19 (Primary Series & Boosters)
Phase
Approved
Status
Commercial
Company
About Arcturus Therapeutics
Arcturus Therapeutics is a pioneer in mRNA therapeutics, leveraging its differentiated LUNAR® delivery and STARR™ self-amplifying mRNA platforms to create a diverse pipeline targeting infectious diseases, rare genetic disorders, and other therapeutic areas. The company achieved a major milestone with the approval and commercialization of its COVID-19 vaccine in Asia, validating its technology and establishing commercial capabilities. With strategic partnerships, including a major collaboration with CSL, Arcturus is advancing multiple clinical and preclinical programs while exploring the broad potential of its mRNA platform beyond vaccines.
View full company profileOther COVID-19 (Primary Series & Boosters) Drugs
| Drug | Company | Phase |
|---|---|---|
| Nuvaxovid® (NVX-CoV2373) | Novavax | Approved/Commercial |